Cargando…

A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis

OBJECTIVE: Variants in CLEC16A have conferred susceptibility to autoimmune diseases in genome-wide association studies. The present work aimed to investigate the locus' involvements in juvenile idiopathic arthritis (JIA) and further explore the association with rheumatoid arthritis (RA), type 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Skinningsrud, Beate, Lie, Benedicte A, Husebye, Eystein S, Kvien, Tore K, Førre, Øystein, Flatø, Berit, Stormyr, Alice, Joner, Geir, Njølstad, Pål R, Egeland, Thore, Undlien, Dag E
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938883/
https://www.ncbi.nlm.nih.gov/pubmed/19734133
http://dx.doi.org/10.1136/ard.2009.114934
_version_ 1782186683656044544
author Skinningsrud, Beate
Lie, Benedicte A
Husebye, Eystein S
Kvien, Tore K
Førre, Øystein
Flatø, Berit
Stormyr, Alice
Joner, Geir
Njølstad, Pål R
Egeland, Thore
Undlien, Dag E
author_facet Skinningsrud, Beate
Lie, Benedicte A
Husebye, Eystein S
Kvien, Tore K
Førre, Øystein
Flatø, Berit
Stormyr, Alice
Joner, Geir
Njølstad, Pål R
Egeland, Thore
Undlien, Dag E
author_sort Skinningsrud, Beate
collection PubMed
description OBJECTIVE: Variants in CLEC16A have conferred susceptibility to autoimmune diseases in genome-wide association studies. The present work aimed to investigate the locus' involvements in juvenile idiopathic arthritis (JIA) and further explore the association with rheumatoid arthritis (RA), type 1 diabetes (T1D) and Addison's disease (AD) in the Norwegian population. METHODS: Three single nucleotide polymorphisms (SNPs) were genotyped in patients with RA (n=809), JIA (n=509), T1D (n=1211) and AD (n=414) and in healthy controls (n=2149). RESULTS: All diseases were associated with CLEC16A, but with different SNPs. The intron 22 SNP, rs6498169, was associated with RA (p=0.006) and JIA (p=0.016) and the intron 19 SNPs, rs12708716/rs12917716, with T1D (p=1×10−5) and AD (p=2×10−4). The RA association was confined to the anti-cyclic citrullinated peptide antibody (anti-CCP) negative subgroup (p=2×10−4). CONCLUSION: This is the first report of a CLEC16A association with JIA and a split of the RA association according to anti-CCP status. Different causative variants underlie the rheumatic versus the organ specific diseases.
format Text
id pubmed-2938883
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BMJ Group
record_format MEDLINE/PubMed
spelling pubmed-29388832010-09-15 A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis Skinningsrud, Beate Lie, Benedicte A Husebye, Eystein S Kvien, Tore K Førre, Øystein Flatø, Berit Stormyr, Alice Joner, Geir Njølstad, Pål R Egeland, Thore Undlien, Dag E Ann Rheum Dis Clinical and Epidemiological Research OBJECTIVE: Variants in CLEC16A have conferred susceptibility to autoimmune diseases in genome-wide association studies. The present work aimed to investigate the locus' involvements in juvenile idiopathic arthritis (JIA) and further explore the association with rheumatoid arthritis (RA), type 1 diabetes (T1D) and Addison's disease (AD) in the Norwegian population. METHODS: Three single nucleotide polymorphisms (SNPs) were genotyped in patients with RA (n=809), JIA (n=509), T1D (n=1211) and AD (n=414) and in healthy controls (n=2149). RESULTS: All diseases were associated with CLEC16A, but with different SNPs. The intron 22 SNP, rs6498169, was associated with RA (p=0.006) and JIA (p=0.016) and the intron 19 SNPs, rs12708716/rs12917716, with T1D (p=1×10−5) and AD (p=2×10−4). The RA association was confined to the anti-cyclic citrullinated peptide antibody (anti-CCP) negative subgroup (p=2×10−4). CONCLUSION: This is the first report of a CLEC16A association with JIA and a split of the RA association according to anti-CCP status. Different causative variants underlie the rheumatic versus the organ specific diseases. BMJ Group 2010-08-01 /pmc/articles/PMC2938883/ /pubmed/19734133 http://dx.doi.org/10.1136/ard.2009.114934 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Clinical and Epidemiological Research
Skinningsrud, Beate
Lie, Benedicte A
Husebye, Eystein S
Kvien, Tore K
Førre, Øystein
Flatø, Berit
Stormyr, Alice
Joner, Geir
Njølstad, Pål R
Egeland, Thore
Undlien, Dag E
A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis
title A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis
title_full A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis
title_fullStr A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis
title_full_unstemmed A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis
title_short A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis
title_sort clec16a variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis
topic Clinical and Epidemiological Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938883/
https://www.ncbi.nlm.nih.gov/pubmed/19734133
http://dx.doi.org/10.1136/ard.2009.114934
work_keys_str_mv AT skinningsrudbeate aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT liebenedictea aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT husebyeeysteins aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT kvientorek aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT førreøystein aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT flatøberit aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT stormyralice aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT jonergeir aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT njølstadpalr aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT egelandthore aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT undliendage aclec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT skinningsrudbeate clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT liebenedictea clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT husebyeeysteins clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT kvientorek clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT førreøystein clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT flatøberit clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT stormyralice clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT jonergeir clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT njølstadpalr clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT egelandthore clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis
AT undliendage clec16avariantconfersriskforjuvenileidiopathicarthritisandanticycliccitrullinatedpeptideantibodynegativerheumatoidarthritis